Scientists discover how ovarian tumors evade immune system
Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association’s Scientific Sessions 2008. “The
Full Post: Rivaroxaban shows promise in patients with acute coronary syndrome
Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body’s immune system, leaving the disease to spread unchecked.
Ovarian cancer is considered to be one of the most aggressive malignancies, killing more than 70 percent of diagnosed women within five years, including an estimated 15,000 this year.
In a two-year series of lab experiments, a team of researchers from the Johns Hopkins University School of Medicine and its Sidney Kimmel Comprehensive Cancer Center showed that fluid secretions from tumors, called ascites, which contain lipids and collect in the space surrounding cancerous ovaries, can totally suppress the action of natural killer T cells in the immune system.
Known as NKTs for short, these special T cells must be activated to do their job of jump-starting the immune response and signaling other kinds of white blood cells to rid the body of diseases or leave healthy tissue alone.
As part of the study, researchers collected lipid-filled ascites from 25 women with ovarian cancer and then exposed the lipid samples to an immune system test to see if they blocked activation of NKT cells.
In a report set to appear in the Dec.1 issue of the journal Clinical Cancer Research , the research team also found this evasive blocking tactic to be virtually exclusive to a specific protein, called CD1d, needed to activate the NKT cells.
Their experiments specifically showed that NKT activation was blocked between 10 percent and 100 percent after test cultures of cells that stimulate NKT cells were exposed to increasing concentrations of tumor-derived ascites.
Disrupted or stalled T cell action has been known to play a key role in the spread of several kinds of cancer, the scientists say. But until now, there was no firm evidence that tied a specific T cell in the body’s defensive immune system to ovarian cancer.
“Our study findings lay out for the first time how ovarian cancer evades a critical check-point in the immune response, opening the door to future drug development that can halt, limit, reverse or even bypass the blockage, permitting CD1d-mediated NKT cell activation,” says immunologist and study senior investigator Mathias Oelke, Ph.D.
According to Oelke, an assistant professor at Johns Hopkins, the research is believed to be the first to demonstrate the clinical effect of ascites on human NKT cells and describe the regulatory role of lipids in cancer progression. Previous studies in mice have confirmed that lipids assist in tumor evasion, he notes. But he says this is the first evidence in humans about the immune-suppressing effects of ascites on NKT cells, which are also abundant in cancers that spread to the abdomen and in other infectious diseases.
“The ultimate goal, of course, is to make sure the immune system can detect the cancer and, we hope, attack and eliminate it,” says study co-investigator Jonathan Schneck, M.D., Ph.D. Schneck, a professor of pathology, medicine and oncology, described the blocking as “rapid and prolonged,” happening within four hours of ascites exposure and remaining constant for the test duration.
When ascites extracted from men and women with another disease, hepatitis C, were exposed to cells that stimulate NKT cells, only two of six ascites samples blocked its activation.
And in another experiment, immune system CD8 “killer” T cells functioned normally, even when their stimulator cells were previously treated with ascites.
Moreover, the blocking action only occurred with ascites. Matching blood serum samples from the women with cancer failed to block NKT activation.
Researchers say their next steps are to evaluate more than a dozen varieties of lipids that exist in the body to determine their specific role, if any, in modulating the blocking of the NKT cell immune response. Their goal, researchers say, is to find links to other diseases and T-cell activity gone awry.
Ovarian cancer cells are “addicted” to a family of proteins produced by the notorious oncogene, MYC. Blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17,
Full Post: Blocking Myc proteins stops ovarian cancer cell cycle in its tracks
Ovarian cancer cells are “addicted” to a family of proteins produced by the notorious oncogene, MYC, and blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec.
Full Post: Researchers stop ovarian cancer cell cycle in its tracks
A new epidemiological study has found that among women who have never used menopausal hormone therapy, obese women are at an increased risk of developing ovarian cancer compared with women of normal weight. Published in the February 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the research indicates that obesity
Full Post: Obesity raises ovarian cancer risk
A new epidemiological study has found that among women who have never used menopausal hormone therapy, obese women are at an increased risk of developing ovarian cancer compared with women of normal weight. Published in the February 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the research indicates that
Full Post: Study links obesity to elevated risk of ovarian cancer
Like tuning a violin to produce strong, elegant notes, researchers at The Wistar Institute have found multiple receptors on the outside of the body’s killer immune system cells which they believe can be selectively targeted to keep the cells in superb infection- and disease-fighting condition. In a study published online November 30 in Nature Immunology,
Full Post: Scientists find key to keeping killer T cells in prime shape for fighting infection, cancer